What it's for (Indications)
- Cyclosporine, a potent immunosuppressant, is primarily indicated for the prophylaxis of organ rejection in patients receiving allogeneic kidney, liver, or heart transplants.
- It is also used in the treatment of chronic rejection in patients who have previously received other immunosuppressive regimens.
- Beyond transplantation, cyclosporine is approved for the management of severe, active rheumatoid arthritis that has been unresponsive to first-line therapies.
- Furthermore, it is indicated for severe, recalcitrant plaque psoriasis in adult patients who are not candidates for or have failed to respond to other systemic therapies.
- Other uses include certain forms of nephrotic syndrome (e.
- g.
- , steroid-dependent or steroid-resistant minimal change nephropathy, focal segmental glomerulosclerosis, membranous nephropathy), severe aplastic anemia, and non-infectious intermediate or posterior uveitis.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cyclosporine is highly individualized and critically depends on the specific indication, the patient's body weight, the type of organ transplant, concomitant medications, and the results of therapeutic drug monitoring (TDM). For transplant recipients, initial doses are typically higher, often ranging from 8 to 12 mg/kg/day orally in two divided doses immediately post-transplant, subsequently tapered based on blood levels and clinical response to maintenance doses of 2 to 6 mg/kg/day. For non-transplant indications like rheumatoid arthritis or psoriasis, initial doses are usually lower, starting around 2.5 mg/kg/day in two divided doses and adjusted based on efficacy, tolerability, and blood concentrations, often not exceeding 4 mg/kg/day. Oral solution and soft gelatin capsules have different bioavailabilities (modified vs. non-modified formulations); therefore, switching between formulations or brands requires careful dose adjustment and close monitoring of cyclosporine blood concentrations to prevent under- or over-immunosuppression and toxicity. Intravenous administration is also possible in specific acute settings. |
Safety & Warnings
Common Side Effects
- Cyclosporine is associated with a wide spectrum of potential side effects, many of which are dose-dependent and can be serious.
- A prominent and significant adverse effect is nephrotoxicity, which can manifest as an acute, reversible decrease in renal function or, with chronic use, as irreversible structural kidney damage.
- Hypertension is very common, often requiring antihypertensive medication.
- Other frequent side effects include hyperlipidemia, hirsutism, gingival hyperplasia, tremor, and headache.
- Gastrointestinal disturbances such as nausea, vomiting, abdominal discomfort, and diarrhea are also reported.
- More serious adverse reactions encompass an increased risk of developing malignancies, particularly lymphomas and skin cancers, and a heightened susceptibility to various infections (bacterial, viral, fungal, protozoal) due to its immunosuppressive action.
- Hepatotoxicity, neurotoxicity (e.
- g.
- , seizures, posterior reversible encephalopathy syndrome [PRES], paresthesia), and electrolyte imbalances such as hyperkalemia and hypomagnesemia, as well as hemolytic uremic syndrome/thrombotic microangiopathy, represent other critical concerns requiring diligent monitoring and management.
Serious Warnings
- Black Box Warning: **WARNING: RENAL IMPAIRMENT, INCREASED RISK OF SERIOUS INFECTIONS AND MALIGNANCIES, HYPERTENSION, NEUROTOXICITY, AND BIOEQUIVALENCE ISSUES** **Renal Impairment:** Cyclosporine can cause dose-dependent and duration-dependent renal dysfunction and structural kidney damage. Baseline and regular monitoring of renal function (serum creatinine, BUN, GFR) and cyclosporine blood concentrations are imperative to minimize this risk. Long-term use necessitates careful consideration of the risk-benefit profile, particularly in non-transplant settings. **Increased Risk of Serious Infections:** Patients receiving cyclosporine are at increased risk for developing serious, sometimes fatal, bacterial, viral, fungal, and protozoal infections, including opportunistic infections. Close monitoring for signs and symptoms of infection is crucial, and prompt initiation of appropriate antimicrobial therapy is often required. **Increased Risk of Malignancies:** Cyclosporine increases the risk of developing malignancies, particularly lymphomas and skin cancers. Patients should limit exposure to sunlight and artificial UV light and undergo regular dermatological screening. The risk of post-transplant lymphoproliferative disorder (PTLD) is also elevated. **Hypertension:** Hypertension is a common and serious side effect of cyclosporine therapy, often requiring antihypertensive treatment. Blood pressure should be monitored regularly, and appropriate management initiated to control hypertension. **Neurotoxicity:** Neurotoxicities, including tremor, headache, paresthesia, and more rarely seizures or posterior reversible encephalopathy syndrome (PRES), have been reported. Patients should be monitored for neurological symptoms, and dose adjustment or discontinuation may be necessary. **Bioequivalence Issues:** Cyclosporine oral solution (non-modified) and soft gelatin capsules (modified) are not bioequivalent and cannot be used interchangeably without physician supervision and careful therapeutic drug monitoring. Switching between cyclosporine formulations or brands, even within modified formulations, requires careful dose adjustments and close monitoring of cyclosporine blood levels to maintain efficacy and prevent toxicity. Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe cyclosporine.
- Cyclosporine carries several critical warnings due to its potent immunosuppressive and potential toxic effects.
- Patients receiving cyclosporine are at significantly increased risk for developing serious and potentially fatal infections with bacteria, viruses, fungi, and protozoa, including opportunistic infections.
- Immunosuppression also increases the risk of developing malignancies, particularly lymphomas and skin cancers; patients should be advised to limit exposure to sunlight and UV light and undergo regular dermatological screening.
- Dose-dependent nephrotoxicity is a primary concern, necessitating rigorous and regular monitoring of renal function (serum creatinine, BUN, GFR) and cyclosporine blood levels to avoid irreversible kidney damage.
- Hypertension is a common adverse effect that often requires pharmacological intervention and close monitoring.
- Hepatotoxicity, neurotoxicity (e.
- g.
- , seizures, tremor, paresthesia, headache, confusion, PRES), and electrolyte disturbances (hyperkalemia, hypomagnesemia) can occur and warrant careful clinical oversight.
- Furthermore, numerous drug interactions, particularly with CYP3A4 inhibitors/inducers, nephrotoxic agents, and potassium-sparing diuretics, can significantly alter cyclosporine blood levels and increase toxicity risk, demanding cautious co-administration and dose adjustments.
- Oral solution and soft gel capsule formulations of cyclosporine (modified vs.
- non-modified) are not bioequivalent; therefore, switching between formulations or brands requires careful dose adjustments and close therapeutic drug monitoring to maintain appropriate blood levels and avoid adverse events.
How it Works (Mechanism of Action)
Cyclosporine exerts its immunosuppressive effects primarily by inhibiting calcineurin, a crucial phosphatase enzyme in the T-lymphocyte activation pathway. Upon entering a T-cell, cyclosporine binds to an intracellular protein called cyclophilin, forming a cyclosporine-cyclophilin complex. This complex then specifically inhibits the phosphatase activity of calcineurin. Calcineurin is typically responsible for dephosphorylating the Nuclear Factor of Activated T-cells (NF-AT), which is a transcription factor essential for the activation of various cytokine genes. By preventing the dephosphorylation of NF-AT, cyclosporine effectively blocks its translocation into the cell nucleus, thereby inhibiting the transcription of several genes coding for pro-inflammatory cytokines, most notably Interleukin-2 (IL-2). IL-2 is critical for T-cell proliferation, differentiation, and overall immune response. This selective inhibition of T-lymphocyte activation leads to a powerful immunosuppressive effect, making cyclosporine highly effective in preventing allograft rejection and managing autoimmune diseases, without causing significant bone marrow depression often seen with cytotoxic agents.